Study S002199

A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07299084
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 40
Start: 2026-01-14
Primary completion: 2026-11
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2; Overweight; Obesity
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:I8F-MC-GPJE

Registered primary outcomes

Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal [Baseline, Day 171 (at 6, 8, 12, 18 and 24 hours after baseline or Day 170 solid test meal)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.